Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Active not recruiting 7Recruiting 5Unknown 2Not yet recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 17Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Cholangiocarcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Carcinoma 4Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Bevacizumab 9pembrolizumab 5lenvatinib 5durvalumab 5atezolizumab 5tremelimumab 3fludarabine 3camrelizumab 3apatinib 3Ipilimumab 3Cyclophosphamide 3regorafenib 2Riluzole 2Radiotherapy 2Nivolumab 2Magnetic Resonance Imaging 2Idarubicin 2Blood Specimen Collection 2Biopsy 2yttrium chloride 1trastuzumab deruxtecan 1spartalizumab 1sintilimab 1pertuzumab 1ferric carboxymaltose 1epigallocatechin gallate 1donafenib 1cemiplimab 1brodalumab 1Yttrium-90 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Liver Neoplasms × durvalumab × Clear all
NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Zhejiang University

Phase 1 Recruiting
72 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Dana-Farber Cancer Institute

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

AHS Cancer Control Alberta

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04988945 2023-09-06

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

The University of Hong Kong

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡